|
Variable
|
HAIC [cases (%)]
|
TACE [cases (%)]
|
P
|
|---|
|
Total
|
38
|
41
| |
|
Age (years)
|
0.638
|
|
≤ 60
|
27 (71.1)
|
27 (65.9)
| |
|
> 60
|
11 (28.9)
|
14 (34.1)
| |
|
Gender
|
0.215
|
|
Male
|
30 (78.9)
|
37 (90.2)
| |
|
Female
|
8 (21.1)
|
4 (9.8)
| |
|
Tumor size (cm)
|
1.000
|
|
< 10
|
12 (31.6)
|
12 (29.3)
| |
|
≥ 10
|
26 (68.4)
|
29 (70.7)
| |
|
Tumor number
|
0.654
|
|
≤ 3
|
18 (47.4)
|
17 (41.5)
| |
|
> 3
|
20 (52.6)
|
24 (58.5)
| |
|
BCLC stage
|
0.338
|
|
A
|
15 (39.5)
|
11 (26.8)
| |
|
B
|
23 (60.5)
|
30 (73.2)
| |
|
Liver cirrhosis
|
0.368
|
|
No
|
20 (52.6)
|
26 (63.4)
| |
|
Yes
|
18 (47.4)
|
15 (36.6)
| |
|
Neutrophil: lymphocyte ratio
|
0.361
|
|
≤ 3
|
22 (57.9)
|
28 (68.3)
| |
|
> 3
|
16 (42.1)
|
13 (31.7)
| |
|
Hemoglobin (g/L)
|
1.000
|
|
< 100
|
1 (2.6)
|
1 (2.4)
| |
|
≥ 100
|
37 (97.4)
|
40 (97.6)
| |
|
Platelet count
|
1.000
|
|
< 100 × 109/L
|
1 (2.6)
|
2 (4.9)
| |
|
≥ 100 × 109/L
|
37 (97.4)
|
39 (95.1)
| |
|
Hepatitis B surface antigen
|
0.434
|
|
Negative
|
2 (5.3)
|
5 (12.2)
| |
|
Positive
|
36 (94.7)
|
36 (87.8)
| |
|
HBV DNA (IU/mL)
|
0.593
|
|
≤ 1000
|
10 (26.3)
|
8 (19.5)
| |
|
> 1000
|
28 (73.7)
|
33 (80.5)
| |
|
PT (s)
|
0.003
|
|
≤ 13.5
|
28 (73.7)
|
40 (97.6)
| |
|
> 13.5
|
10 (26.3)
|
1 (2.4)
| |
|
ALT (U/L)
|
1.000
|
|
≤ 40
|
17 (44.7)
|
18 (43.9)
| |
|
> 40
|
21 (55.3)
|
23 (56.1)
| |
|
ALB (g/L)
|
0.655
|
|
≤ 40
|
20 (52.6)
|
19 (46.3)
| |
|
> 40
|
18 (47.4)
|
22 (53.7)
| |
|
TBIL (μmol/L)
|
0.284
|
|
≤ 20.5
|
27 (71.1)
|
34 (82.9)
| |
|
> 20.5
|
11 (28.9)
|
7 (17.1)
| |
|
AFP (ng/mL)
|
0.813
|
|
≤ 400
|
12 (31.6)
|
15 (36.6)
| |
|
> 400
|
26 (68.4)
|
26 (63.4)
| |
-
HAIC hepatic artery infusion chemotherapy; TACE transarterial chemoembolization; BCLC Barcelona Clinic Liver Cancer; HBV hepatitis B virus; PT prothrombin time; ALT alanine transaminase; ALB albumin; TBIL total bilirubin; AFP alpha-fetoprotein
-
P values were calculated using a two-sided Chi square test
